Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 270 Results

December 14, 2015

Pharmaceutical Industry Leader James Dolan Joins Relmada Therapeutics Advisory Team

December 11, 2015

U.S. Federal Court Issues Temporary Restraining Order Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern

December 10, 2015

Relmada Therapeutics Announces Additional Information Regarding Positive Topline Results for Proof-of-Concept Study with BuTab

December 9, 2015

Relmada Therapeutics Files Federal Lawsuit Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern to Protect Interests of Relmada Stockholders

December 9, 2015

Relmada Therapeutics Announces Positive Topline Results for Proof-of-Concept Study with BuTab

December 7, 2015

Relmada Therapeutics to Mail Letter to Stockholders Highlighting Laidlaw & Company’s Questionable Business Practices and Conduct

December 1, 2015

Relmada Therapeutics to Present at LD Micro Main Event

November 12, 2015

Relmada Therapeutics Strengthens its Board of Directors with the Appointment of Maged Shenouda and Paul Kelly

November 5, 2015

Relmada Therapeutics Responds to 13D Filing by Laidlaw

October 13, 2015

Relmada Therapeutics to Present at 14th Annual BIO Investor Forum

«...20 212223 24 25...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top